XSHG
600227
Market cap1.02bUSD
Oct 09, Last price
4.12CNY
1D
1.98%
1Q
60.94%
Jan 2017
-43.17%
IPO
40.90%
Name
Guizhou Chitianhua Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guizhou Chitianhua Co.,Ltd. engages in the chemical and pharmaceutical businesses in China. The company offers urea fertilizers; synthetic ammonia and ammonium sulfate; and sulfuric acid, industrial nitrogen, industrial ammonia, and industrial hydrogen, as well as basic chemical products and their deep-processed and by-products. It also produces and sells pharmaceuticals; medical equipment; and drugs for diabetes, cardiovascular, dermatology, gynecological, digestive system, endocrine, and psychotropic diseases. In addition, the company engages in the production of Chinese and western patent medicines; class II clinical laboratory analysis instruments; and sanitary products, as well as sales of self-produced products. Further, it is involved in the manufacture and sales of special and daily chemical products; provision of technical development, consultation, exchanges, and services; technology transfer and promotion; coal washing; sales of coal products; import and export of technology and goods; motor vehicle repair and maintenance; health care products; retailing of prepackaged foods; software technology development and services; data processing services; health consultation; production and sales of cosmetics; planting of Chinese herbal medicines; sales and storage services of cells; research on stem cell biotechnology and gene technology; production of biological products; investment in coal construction projects; and sales of industrial and mining products, mining equipment and spare parts. Guizhou Chitianhua Co.,Ltd. was formerly known as Guizhou Salvage Pharmaceutical Co.,Ltd. and changed its name to Guizhou Chitianhua Co.,Ltd. in May 2023. The company was founded in 1998 and is based in Guiyang, China.
Key people
Linhong Ding
Chairman of the Board, General Manager · since 2018
Ning Liu
Chief Financial Officer · since 2025
Bilu Che
Deputy General Manager · since 2008
Honglin Chen
Deputy General Manager · since 2021
Yang Lin
Deputy General Manager · since 2022
Hongyan Wu
Deputy General Manager · since 2023
Zhenghong Xian
Deputy General Manager, Secretary of the Board · since 2018
Linhui Ding
Director · since 2015
Minhong Gao
Executive Deputy General Manager, Director · since 2019
Zhihong Yao
Director · since 2023
Zongzhen Yu
Director · since 2023
Qiyong Fan
Independent Director · since 2014
Pu Wang
Independent Director · since 2020
Guang Xu
Independent Director · since 2023
Headquarters & legal address
贵州省贵阳市清镇市医药园区
贵阳市, GZ 100000
CN
贵阳市, GZ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||